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Abstract
Background: Pseudomonas aeruginosa is a pathogen associated with cystic fibrosis that has potential to decrease
lung function and cause respiratory failure. Paranasal sinuses are increasingly recognised as potential reservoirs for
intermittent colonisation by P. aeruginosa. This case documents investigation and outcome of P. aeruginosa
recurrence in a male paediatric patient over an eight year period.
Case presentation: A 12 year old Irish male paediatric cystic fibrosis patient experienced intermittent culturing of
P. aeruginosa from the oropharyngeal region, indicating chronic infection of the sinuses despite absence of symptoms,
retaining good lung function, and normal bronchoscopy and bronchoalveloar lavage. However, P. aeruginosa was isolated
from a sinus wash-out and was identified as a unique strain of P. aeruginosa that was also cultured from cough swabs.
Despite treatment, successful eradication from the paranasal sinuses was not achieved.
Conclusions: Few reports have addressed the paranasal sinuses as a reservoir for lung infection in cystic fibrosis patients
despite increased recognition of the need to investigate this niche. In this case, attempts at eradication of P. aeruginosa
present in paranasal sinuses including oral and nebulised antimicrobials proved unsuccessful. However, detection of
P. aeruginosa in the paranasal sinuses instigated antimicrobial treatment which may have contributed to prevention of
migration to the lower airways. Our outcome provides additional insight and may indicate utility of nasal lavage or nasal
endoscopy in paediatric cystic fibrosis patients’ annual review clinic visits.
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Background
The Cystic Fibrosis (CF) patient airway is defective in
ciliary function; resulting, due to ineffective removal, in a
mucus-rich environment [1] favouring growth of bacteria
[2], including potential pathogens, such as, but not limited
to, Staphylococcus aureus, Haemophilus influenza and
Pseudomonas aeruginosa [1] associated with chronic
infection [3], decreased lung function [4] and accelerated
respiratory disease [5]. Consequently, risk of mortality for
paediatric CF patients with lower airway infection by P.
aeruginosa has been reported as almost three times higher
than for those without [5].
There has been limited study of the paranasal sinuses as
reservoirs for P. aeruginosa [6–11]. However, it is believed
that due to poor mucociliary clearance in the paranasal
sinuses and the lower airways, and physiological similar-
ities between the membranes of the sinuses and the
conductive bronchi, that P. aeruginosa migration from the
sinuses to the lower airways may occur [6, 12]. Chronic P.
aeruginosa infection is often preceded by a period of
intermittent colonisation of the airways [8, 13], sometimes
in the absence of symptoms of infection or immunological
responses [14]. Adding additional complexity, in the con-
text of managing CF patients successfully, the colonising
P. aeruginosa may undergo substantial genetic adaptation
and diversification into subpopulations with varying pheno-
typic traits (including nutient utilisation, growth rates, exo-
polysaccharide production and antimicrobial resistances)
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and, with regard to microbiological analysis, differing
colony morphologies [1, 8, 15, 16].
The paranasal sinuses may become a focus for regular
examination or antimicrobial treatment in CF patients,
such as functional endoscopic sinus surgery promoted
by Danish clincians [13, 17]. Similarly, the oral cavity
has been identified as a potential reservoir for patho-
genic bacteria in CF patients [18, 19], with failure to
determine presence of pathogens potentially detrimental
to CF patients. In this case, we focus on and describe
intermittent P. aeruginosa colonisation of the oropha-
ryngeal region of a paediatric patient and, supporting
the rationale of the Danish group, the role of the parana-
sal sinuses specifically as reservoirs that contributed to
our failure to eradicate the pathogen despite successive
antimicrobial administration.
Case presentation
Ethical approval and informed consent for this study
was approved by the HSE Mid-Western Regional Hos-
pital Research Ethics Committee. A 12 year old asymp-
tomatic patient (homozygous for Phe508del) with good
lung function (mean forced expiratory volume -FEV1)
from March 2009 to June 2014: 91.6 % ± 1.46 %) and
normal bronchoscopy with no bacterial growth from
two bronchoalveloar lavages (BAL) (considered the ‘gold
standard’ method for collection of samples from the
lower airways [20, 21]), displayed intermittent chronic P.
aeruginosa infection of the oropharyngeal region (or at least
detection using the oropharyngeal swab) between Septem-
ber 2006 to September 2014. This caused the patient’s par-
ents to persistently submit elevated numbers of cough
swabs for microbiological investigation. Eradication regi-
mens comprised nebulised (via both mouth and nose) and
oral antimicrobials, which appeared to clear the oropharyn-
geal region of P. aeruginosa, albeit transiently, but ultim-
ately proved ineffective.
P. aeruginosa was first isolated in August 2006 from a
cough swab, when the patient was four years of age and,
thereafter, isolated once each year for three subsequent
years. Microbiological assessment was in accordance
with Health Protection Agency Standard Operating
Procedure (HPA SOP) 57 guidelines. On each occasion
that P. aeruginosa was identified, the patient underwent
eradication regimens until three follow up monthly cough
swabs were negative for growth. Samples obtained from the
patient remained clear of P. aeruginosa from September
2008 until May 2010, when the annual recurrence pattern
was re-established for three subsequent years. In December
2010, the detection of P. aeruginosa resulted in adminis-
tration of ciprofloxacin (oral – 500 mg) and tobramycin
(nebulised – 300 mg), both b.i.d. for 28 days. However, the
frequency of P. aeruginosa colonisation increased from
March 2013, evident approximately every three months
until January 2014. Although the patient never exhibited
symptoms of sinusitis, and although no general anaesthe-
sia and involvement of an ear, nose and throat (ENT) sur-
geon (JF) was necessary, nevertheless, a bilateral antral
washout was performed in Dec 2012 and Sept 2014 as the
patient was unable to expectorate and the concept of the
paranasal sinuses acting as a reservoir for P. aeruginosa
was considered.
P. aeruginosa was isolated from the right antral washing;
therefore, the patient underwent the same eradication
regimen as before, supplemented by maintenance therapy
of tobramycin (300 mg per 5 mL nebulised solution) and
colistin (2 M IU) administered via a face mask that allowed
the antimicrobials to pass through the nasal cavity. The
patient was encouraged to breathe predominantly through
the nose during the nebulisation sessions to ensure max-
imum administration to the nasal cavity. Following this ex-
tended treatment, between February and September 2014
cough swabs remained P. aeruginosa-free. In September
2014, the patient underwent repeat antral sinus washing,
bronchoscopy and cough swab collection. P. aeruginosa
was again isolated from the right antral washing. The
lower airways remained clear of Pseudomonas.
P. aeruginosa isolates underwent molecular (Variable
Number Tandem Repeat) and phenotypic characterisation
(Table 1). Antimicrobial sensitivity profiles were generated
for each isolate (from August 2006 until September 2014)
based on CLSI and EUCAST guidelines [22, 23] (Table 2).
VNTR analysis demonstrated that all isolates represented
the same unique P. aeruginosa strain. Phenotypic analysis
classified all except two isolates (September 2013 and
2014) as mucoid, a characteristic not seen in the majority
(6 out of 7) of isolates previously. Isolates were proteolytic
and siderophore producing (Table 1). All isolates were
susceptible to tobramycin, ciprofloxacin and meropenem,
while the majority (all but antral washing Sept 2014) were
also susceptible to pipercillin/tazobactum (Table 2).
Conclusions
Our findings demonstrate that the paranasal sinuses acted
as protected reservoirs for P. aeruginosa as verified by
VNTR profiling, supporting previous (albeit few) reports
[13, 17]. As with other researchers [16, 24, 25], we found
indications of adaptation of the P. aeruginosa strain,
whereby prior to March 2013, all but one P. aeruginosa
isolate from our patient were classified (based on colony
morphology) as non-mucoid, whereas on and after this
date, four of six isolates were phenotypically mucoid
(Table 1). Such mucoidy is due to an overproduction of
polysaccharide alginate, which contributes to biofilm for-
mation [26] and increased resistance to antimicrobials
[27]. It is believed that a non-mucoid phenotype is
most often associated with isolates from early infection
while mucoid strains are more frequently associated
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with established infection [3] and, indeed, poorer
patient prognosis [28]. In our study, the same isolates
were identified as proteolytic (associated with damage
to tissue [29]) and siderophore producing (linked to
bacterial virulence [30, 31]) producing (Table 1), al-
though no pattern of changing protease or siderophore
activity was discernible.
Antimicrobials are used commonly in treatment of initial
colonisation of P. aeruginosa to postpone chronic infection
and respiratory dysfunction, often delivered orally (e.g.,
ciprofloxacin) or nebulised (e.g., tobramycin) [13, 32, 33].
In this case, analogous to the approach adopted successfully
elsewhere [34, 35], additional maintenance therapy com-
prised nebulised tobramycin and colomycin on alternate
months, for six months. However, in our case, this ultim-
ately proved unsuccessful. Other groups have recognised
the challenge of eradicating P. aeruginosa from the parana-
sal sinuses using existing approaches and have have begun
Table 1 Phenotypic profile of Pseudomonas aeruginosa isolates from a paediatric patient over n 8 year period
Phenotypic classification




11/08/06a Cough Swab - -
23/08/07c Cough Swab - -
07/08/08c,d Cough Swab - -
05/05/10b Cough Swab - -
14/12/10 Cough Swab - +
22/04/11b Cough Swab - -
10/04/12b,c,d Cough Swab - -
23/03/13 Cough Swab - + +++ +++
06/06/13c Cough Swab - + ++ +
30/09/13 Cough Swab - - +++ ++
20/12/13 Cough Swab - + + +
23/01/14e Antral Washing - + ++ +++
11/09/14 Antral Washing - - + +
aFirst identification of Pseudomonas aeruginosa. bP. aeruginosa growth described as “scanty” by University Hospital Limerick microbiology laboratory.
cStaphylococcus aureus also identified in addition to P. aeruginosa
dHaemophilus parainfluenzae also identified in addition to P. aeruginosa. ePseudomonas fluorescens also identified in addition to P. aeruginosa
Where + = low, ++ = intermediate, +++ = high
Table 2 Antimicrobial sensitivity profile for Pseudomonas aeruginosa from a paediatric patient over an 8 year period
CLSI Guidelines EUCAST Guidelines
Disk content (μg) 2006 2007 2008 2010 2011 2012 Disk content (μg) 2013 2014
11/8 23/8 6/8 5/5 14/12 22/4 10/4 26/3 6/6 30/9 20/12 23/1 23/1a 11/9a
Drug
Ofloxacin 5 S S NT NT NT NT NT 0 NT NT NT NT NT NT NT
Pipercillin/
Tazobactum
100/10 S S S S S S S 36 S S S S S R S
Ceftazidime 30 S S S S S S S 10 S S S S S S S
Tobramycin 10 S S S S S S S 10 S S S S S S S
Ciprofloxacin 5 NT S NT S S S S 5 S S S S S S S
Amikacin 30 NT S NT NT NT NT NT 30 NT NT NT NT NT NT NT
Aztreoman 30 NT S NT NT NT NT S 30 S I I I I I I
Colistin (E-Test) 10 NT S NT NT NT NT NT 10 NT NT S S S S S
Imipenem 10 NT S NT NT NT NT NT 10 NT NT NT NT NT NT NT
Meropenem 10 NT S S S S S S 10 S S S S S S S
S Susceptible, I Intermediate, R Resistant and NT Not Tested
aP. aeruginosa isolated from antral washing
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to evaluate novel strategies such as inhalation of tobra-
mycin using vibrating [36] or pulsating [37] aerosols or
addition of hyaluronate to nasal sprays [38].
In our case, although the eradication regimen proved
unsuccessful in decolonising the paranasal sinuses of P.
aeruginosa, we believe that detection of the pathogen
instigated antimicrobial treatment that may have contrib-
uted to prevention of migration to the lower airways and,
therefore, preventing chronic infection of the lower air-
ways. Our case supports the rationale for assessment of the
paranasal sinuses as potential P. aeruginosa reservoirs in
CF patients displaying intermittent colonisation patterns
albeit that the currently available techniques are invasive,
require general anaesthesia and prudent antimicrobial use
as they may themselves, due to physical disruption, cause
migration of bacteria to other airways.
Consent
Written informed consent was obtained from the patient
and his parents for publication of this case report. A copy
of the written consent is available for review by the Editor
of this journal.
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